Newtopia Past Earnings Performance
Past criteria checks 0/6
Newtopia has been growing earnings at an average annual rate of 4.9%, while the Healthcare industry saw earnings growing at 0.3% annually. Revenues have been growing at an average rate of 17.1% per year.
Key information
4.9%
Earnings growth rate
53.3%
EPS growth rate
| Healthcare Industry Growth | -6.7% |
| Revenue growth rate | 17.1% |
| Return on equity | n/a |
| Net Margin | -47.0% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Newtopia makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 11 | -5 | 6 | 3 |
| 30 Jun 23 | 11 | -6 | 7 | 4 |
| 31 Mar 23 | 11 | -7 | 8 | 4 |
| 31 Dec 22 | 11 | -8 | 8 | 4 |
| 30 Sep 22 | 10 | -8 | 9 | 4 |
| 30 Jun 22 | 11 | -7 | 8 | 3 |
| 31 Mar 22 | 11 | -7 | 8 | 3 |
| 31 Dec 21 | 10 | -8 | 9 | 3 |
| 30 Sep 21 | 11 | -9 | 10 | 3 |
| 30 Jun 21 | 10 | -9 | 10 | 4 |
| 31 Mar 21 | 10 | -9 | 10 | 3 |
| 31 Dec 20 | 11 | -8 | 9 | 3 |
| 30 Sep 20 | 10 | -9 | 9 | 3 |
| 30 Jun 20 | 9 | -9 | 8 | 3 |
| 31 Mar 20 | 8 | -10 | 7 | 3 |
| 31 Dec 19 | 6 | -10 | 7 | 3 |
| 30 Sep 19 | 5 | -9 | 5 | 2 |
| 30 Jun 19 | 5 | -8 | 5 | 2 |
| 31 Mar 19 | 4 | -7 | 5 | 2 |
| 31 Dec 18 | 3 | -6 | 4 | 2 |
| 31 Dec 17 | 2 | -8 | 6 | 2 |
Quality Earnings: NEWU is currently unprofitable.
Growing Profit Margin: NEWU is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NEWU is unprofitable, but has reduced losses over the past 5 years at a rate of 4.9% per year.
Accelerating Growth: Unable to compare NEWU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NEWU is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (6.7%).
Return on Equity
High ROE: NEWU's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.